SCHEMBL12437998

SCHEMBL12437998

Cc1cc(C)cc(Nc2nccc(Nc3cc(C4CC4)n[nH]3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 8/20 0.50
▸ NEK1 Q96PY6 1/20 0.49
▸ KDR P35968 2/20 0.48
▸ BRD4 O60885 1/20 0.45
▸ BRD2 P25440 1/20 0.45
▸ BRD3 Q15059 1/20 0.45
▸ BRDT Q58F21 1/20 0.45
▸ FGFR1 P11362 1/20 0.45
▸ SRC P12931 4/20 0.44
▸ SYK P43405 4/20 0.43
▸ AKT1 P31749 1/20 0.43
▸ TGFBR1 P36897 1/20 0.43
▸ GSK3A P49840 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ STK4 Q13043 1/20 0.43
▸ STK3 Q13188 1/20 0.43
▸ BMPR2 Q13873 1/20 0.43
▸ STK26 Q9P289 1/20 0.43
▸ STK24 Q9Y6E0 1/20 0.43
▸ ZAP70 P43403 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158052 0.87 NEK1 (0.53) IGF1RNEK1SRCAKT1TGFBR1
SCHEMBL18901334 0.86 IGF1R (0.53) IGF1RNEK1KDRFGFR1SRC
SCHEMBL12785351 0.86 NEK1 (0.66) IGF1RNEK1FGFR1SRCAKT1
SCHEMBL11348830 0.86 IGF1R (0.69) IGF1RNEK1KDRFGFR1SRC
SCHEMBL2158172 0.85 NEK1 (0.54) IGF1RNEK1FGFR1SRCSYK
SCHEMBL11344820 0.84 IGF1R (0.66) IGF1R
SCHEMBL14050460 0.84 IGF1R (0.50) IGF1RNEK1KDRFGFR1SRC
SCHEMBL11342663 0.84 IGF1R (0.69) IGF1RNEK1SRCAKT1TGFBR1
SCHEMBL12045459 0.83 SRC (0.57) IGF1RNEK1SRCSYK
SCHEMBL11410231 0.82 IGF1R (0.54) IGF1RNEK1KDRFGFR1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841760-B1 PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2011-08-10 — — EP disclosed
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 — — WO disclosed
WO-2008005538-A2 METHODS OF USING IGF1R AND ABL KINASE MODULATORS EXELIXIS, INC. (US) 2008-01-10 — — WO disclosed
Send feedback